Nicole Cortez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Cortez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cecilia Villegas
Departamento de Ciencias Biológicas y Químicas, Facultad de Recursos Naturales, Universidad Católica de Temuco, Rudecindo Ortega, Temuco 4780000, Chile
4 shared publications - Cristian Paz
Laboratory of Natural Products & Drug Discovery, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco 4780000, Chile
4 shared publications - Jaime R. Cabrera-Pardo
Laboratorio de Química Aplicada y Sustentable (LabQAS), Departamento de Química, Universidad del Bío-Bío, Avenida Collao 1202, Concepcion 4051381, Chile
4 shared publications - Viviana Burgos
Departamento de Ciencias Biológicas y Químicas, Facultad de Recursos Naturales, Universidad Católica de Temuco, Rudecindo Ortega, Temuco 4780000, Chile
3 shared publications - Leandro Ortiz
Instituto de Ciencias Químicas, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5110566, Chile
2 shared publications - Ayorinde Victor Ogundele
Laboratory of Natural Products & Drug Discovery, Center CEBIM, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco 4780000, Chile
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 617
Antarctic Fungi as a Source of Alternative Antifungal Compounds: Bioactive Metabolites from South Shetland Islands Fungi with Activity Against Candida Species
The emergence of drug-resistant Candida species has intensified efforts to discover novel bioactive compounds. Antarctic environments harbor psychrophilic microorganisms that produce unique secondary metabolites adapted to extreme conditions, making them valuable natural resources for drug discovery. During the 2020 Antarctic Scientific Expedition, we collected 19 sediment samples from the South Shetland Islands and isolated 14 fungal strains belonging to Cladosporium, Oidiodendron, Penicillium, Pseudeurotium, and Pseudogymnoascus genera. Total organic extracts obtained from 21-day cultures were evaluated for antimicrobial activity against pathogenic yeasts and bacteria. Oidiodendron sp. (ECA57-20) and Pseudogymnoascus sp. (ECA57-61) demonstrated strong anti-Candida activity with minimum inhibitory concentrations ranging from 7.81 to 62.5 µg/mL against C. albicans, Pichia kudriavzevii (C. krusei), C. tropicalis, Nakaseomyces glabratus (C. glabrata), and Clavispora lusitaniae (C. lusitaniae). GC-MS (gas chromatography mass spectrometry) metabolomic profiling suggests a broad diversity of secondary metabolites across active strains, which may contribute to the observed biological activities. These findings support the potential of Antarctic fungi as sources of alternative antifungal agents.
- 10 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 617
Open AccessAntarctic Fungi as a Source of Alternative Antifungal Compounds: Bioactive Metabolites from South Shetland Islands Fungi with Activity Against Candida Species
The emergence of drug-resistant Candida species has intensified efforts to discover novel bioactive compounds. Antarctic environments harbor psychrophilic microorganisms that produce unique secondary metabolites adapted to extreme conditions, making them valuable natural resources for drug discovery. During the 2020 Antarctic Scientific Expedition, we collected 19 sediment samples from the South Shetland Islands and isolated 14 fungal strains belonging to Cladosporium, Oidiodendron, Penicillium, Pseudeurotium, and Pseudogymnoascus genera. Total organic extracts obtained from 21-day cultures were evaluated for antimicrobial activity against pathogenic yeasts and bacteria. Oidiodendron sp. (ECA57-20) and Pseudogymnoascus sp. (ECA57-61) demonstrated strong anti-Candida activity with minimum inhibitory concentrations ranging from 7.81 to 62.5 µg/mL against C. albicans, Pichia kudriavzevii (C. krusei), C. tropicalis, Nakaseomyces glabratus (C. glabrata), and Clavispora lusitaniae (C. lusitaniae). GC-MS (gas chromatography mass spectrometry) metabolomic profiling suggests a broad diversity of secondary metabolites across active strains, which may contribute to the observed biological activities. These findings support the potential of Antarctic fungi as sources of alternative antifungal agents.
- Open Access
- 19 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 867
Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
Chemotherapeutic drugs and radiotherapy are fundamental treatments to combat cancer, but, often, the doses in these treatments are restricted by their non-selective toxicities, which affect healthy tissues surrounding tumors. On the other hand, drug resistance is recognized as the main cause of chemotherapeutic treatment failure. Rosmarinic acid (RA) is a polyphenol of the phenylpropanoid family that is widely distributed in plants and vegetables, including medicinal aromatic herbs, consumption of which has demonstrated beneficial activities as antioxidants and anti-inflammatories and reduced the risks of cancers. Recently, several studies have shown that RA is able to reverse cancer resistance to first-line chemotherapeutics, as well as play a protective role against toxicity induced by chemotherapy and radiotherapy, mainly due to its scavenger capacity. This review compiles information from 56 articles from Google Scholar, PubMed, and ClinicalTrials.gov aimed at addressing the role of RA as a complementary therapy in cancer treatment.
- 19 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 867
Open AccessTherapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
Chemotherapeutic drugs and radiotherapy are fundamental treatments to combat cancer, but, often, the doses in these treatments are restricted by their non-selective toxicities, which affect healthy tissues surrounding tumors. On the other hand, drug resistance is recognized as the main cause of chemotherapeutic treatment failure. Rosmarinic acid (RA) is a polyphenol of the phenylpropanoid family that is widely distributed in plants and vegetables, including medicinal aromatic herbs, consumption of which has demonstrated beneficial activities as antioxidants and anti-inflammatories and reduced the risks of cancers. Recently, several studies have shown that RA is able to reverse cancer resistance to first-line chemotherapeutics, as well as play a protective role against toxicity induced by chemotherapy and radiotherapy, mainly due to its scavenger capacity. This review compiles information from 56 articles from Google Scholar, PubMed, and ClinicalTrials.gov aimed at addressing the role of RA as a complementary therapy in cancer treatment.
- Top Cited PapersOpen Access
- 11 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7631
Adjuvant Properties of Caffeic Acid in Cancer Treatment
Caffeic acid (CA) is a polyphenol belonging to the phenylpropanoid family, commonly found in plants and vegetables. It was first identified by Hlasiwetz in 1867 as a breakdown product of caffetannic acid. CA is biosynthesized from the amino acids tyrosine or phenylalanine through specific enzyme-catalyzed reactions. Extensive research since its discovery has revealed various health benefits associated with CA, including its antioxidant, anti-inflammatory, and anticancer properties. These effects are attributed to its ability to modulate several pathways, such as inhibiting NFkB, STAT3, and ERK1/2, thereby reducing inflammatory responses, and activating the Nrf2/ARE pathway to enhance antioxidant cell defenses. The consumption of CA has been linked to a reduced risk of certain cancers, mitigation of chemotherapy and radiotherapy-induced toxicity, and reversal of resistance to first-line chemotherapeutic agents. This suggests that CA could serve as a useful adjunct in cancer treatment. Studies have shown CA to be generally safe, with few adverse effects (such as back pain and headaches) reported. This review collates the latest information from Google Scholar, PubMed, the Phenol-Explorer database, and ClinicalTrials.gov, incorporating a total of 154 articles, to underscore the potential of CA in cancer prevention and overcoming chemoresistance.
- 11 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7631
Top Cited PapersOpen AccessAdjuvant Properties of Caffeic Acid in Cancer Treatment
Caffeic acid (CA) is a polyphenol belonging to the phenylpropanoid family, commonly found in plants and vegetables. It was first identified by Hlasiwetz in 1867 as a breakdown product of caffetannic acid. CA is biosynthesized from the amino acids tyrosine or phenylalanine through specific enzyme-catalyzed reactions. Extensive research since its discovery has revealed various health benefits associated with CA, including its antioxidant, anti-inflammatory, and anticancer properties. These effects are attributed to its ability to modulate several pathways, such as inhibiting NFkB, STAT3, and ERK1/2, thereby reducing inflammatory responses, and activating the Nrf2/ARE pathway to enhance antioxidant cell defenses. The consumption of CA has been linked to a reduced risk of certain cancers, mitigation of chemotherapy and radiotherapy-induced toxicity, and reversal of resistance to first-line chemotherapeutic agents. This suggests that CA could serve as a useful adjunct in cancer treatment. Studies have shown CA to be generally safe, with few adverse effects (such as back pain and headaches) reported. This review collates the latest information from Google Scholar, PubMed, the Phenol-Explorer database, and ClinicalTrials.gov, incorporating a total of 154 articles, to underscore the potential of CA in cancer prevention and overcoming chemoresistance.
- Open Access
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5189
Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
Chemotherapeutic drugs are indispensable in cancer treatment, but their effectiveness is often lessened because of non-selective toxicity to healthy tissues, which triggers inflammatory pathways that are harmful to vital organs. In addition, tumors’ resistance to drugs causes failures in treatment. Chlorogenic acid (5-caffeoylquinic acid, CGA), found in plants and vegetables, is promising in anticancer mechanisms. In vitro and animal studies have indicated that CGA can overcome resistance to conventional chemotherapeutics and alleviate chemotherapy-induced toxicity by scavenging free radicals effectively. This review is a summary of current information about CGA, including its natural sources, biosynthesis, metabolism, toxicology, role in combatting chemoresistance, and protective effects against chemotherapy-induced toxicity. It also emphasizes the potential of CGA as a pharmacological adjuvant in cancer treatment with drugs such as 5-fluorouracil, cisplatin, oxaliplatin, doxorubicin, regorafenib, and radiotherapy. By analyzing more than 140 papers from PubMed, Google Scholar, and SciFinder, we hope to find the therapeutic potential of CGA in improving cancer therapy.
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5189
Open AccessTherapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
Chemotherapeutic drugs are indispensable in cancer treatment, but their effectiveness is often lessened because of non-selective toxicity to healthy tissues, which triggers inflammatory pathways that are harmful to vital organs. In addition, tumors’ resistance to drugs causes failures in treatment. Chlorogenic acid (5-caffeoylquinic acid, CGA), found in plants and vegetables, is promising in anticancer mechanisms. In vitro and animal studies have indicated that CGA can overcome resistance to conventional chemotherapeutics and alleviate chemotherapy-induced toxicity by scavenging free radicals effectively. This review is a summary of current information about CGA, including its natural sources, biosynthesis, metabolism, toxicology, role in combatting chemoresistance, and protective effects against chemotherapy-induced toxicity. It also emphasizes the potential of CGA as a pharmacological adjuvant in cancer treatment with drugs such as 5-fluorouracil, cisplatin, oxaliplatin, doxorubicin, regorafenib, and radiotherapy. By analyzing more than 140 papers from PubMed, Google Scholar, and SciFinder, we hope to find the therapeutic potential of CGA in improving cancer therapy.